Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (6): 368-369.
Previous Articles Next Articles
GUO Hao-ning, WU Si-lin, ZHANG Li, HE Miao-quan*
Received:
2018-08-03
Revised:
2018-08-03
Online:
2018-06-15
Published:
2018-08-03
CLC Number:
GUO Hao-ning, WU Si-lin, ZHANG Li, HE Miao-quan. One Case of Skin Rash and Severe Thrombocytopenia Induced by Oxcarbazepine Tablets[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 368-369.
[1] Shankar B R.Quetiapine-induced leucopenia and thrombocytopenia[J]. Psychosomatics, 2007, 8(6): 530-531. [2] 孙燕, 仵钊锋. 度洛西汀临床不良反应分析[J]. 河南大学学报(医学版), 2015,(2): 142-144. [3] 王健, 马辛. 丙戊酸镁缓释片致血小板减少症1例[J]. 临床精神医学杂志, 2016, 26(3): 216. [4] 汪作为, 陈银娣. 喹硫平所致血小板减少症1例[J]. 精神医学杂志, 2009, 22(5): 384. [5] 李焕芬, 陈建华, 朱利芳. 奥卡西平片致血小板减少1例[J]. 中国药物警戒, 2015, 12(11): 700. [6] 王丹. 诺华公司警告奥卡西平的严重皮肤反应[J]. 中国药物警戒, 2005, 2(4): 252. [7] 杨华, 魏晶, 王嘉仡, 等. 药品不良反应/事件报告评价方法研究[J]. 中国药物警戒, 2009, 6(10): 581-584. [8] 卫生部合理用药专家委员会. 中国医师药师临床用药指南[M]. 1版. 重庆: 重庆出版社, 2009: 1132-1133. [9] Schmidt D, Elger C E.What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?[J]. Epilepsy Behavior, 2004, 5(5): 627-635. [10] 仇锦春, 廖清船, 张永, 等. 奥卡西平致皮疹、血小板减少性紫癜1例[J]. 中国现代应用药学, 2011, 28(11): 1067-1068. [11] He X, Kang S, Wang F, et al.Oxcarbazepine-related thrombocytopenic purpura[J]. Journal of Clinical Psychopharmacology, 2011, 31(1): 137-138. [12] 方舒, 龚志成. 奥卡西平的不良反应[J]. 中国当代儿科杂志, 2015, 17(4): 414-419. [13] 何学莲, 王芳琳, 吴革菲, 等. 奥卡西平诱发的Stevens-Johnson综合征的临床特点及基因表达[J]. 中华实用儿科临床杂志, 2011, 26(5): 360-362. [14] Tutorcrespo M J, Hermida J, Tutor J C.Relation of blood platelet count during carbamazepine and oxcarbazepine treatment with daily dose, and serum concentrations of carbamazepine, carbama-zepine-10,11-epoxide, and 10-hydroxycarbazepine[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2007, 151(1): 91-94. [15] Hurley J S, Roberts M, Solberg L I.Laboratory safety monitoring of chronic medications in ambulatory care settings[J]. J Gen Intern Med, 2005, 20(4): 331-333. [16] Martinez W, Ingenito A, Blakeslee M, et al.Efficacy, safety, and tolerability of oxcarbazepine monotherapy[J]. Epilepsy Behavior, 2006, 9(3): 448-456. |
[1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
[2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
[3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
[4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
[6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
[7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
[8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
[9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
[10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
[11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
[12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
[13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
[14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
[15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||